Watch SABS. Know when insiders buy.
One email the day a filing lands. Free.
SABS
SAB Biotherapeutics, Inc.
3.29
−0.06 −1.79%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
81
PASS · shorts 81
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $299.3MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.8MNET CASH —52W 1.95 – 4.59SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$23.4M | −$22.5M | — | -0.28 | −$9.8M | $1.6M | −$11.4M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$20M | −$18.9M | — | -0.35 | −$14.3M | $983K | −$15.3M | Aug 6 |
| Q4 2025 · Dec 31derived | — | — | — | −$15.8M | −$16.9M | — | -0.46 | −$16.8M | — | — | Mar 9 |
| Q3 2025 · Sep 30 | — | — | — | −$12.7M | $45.4M | — | -0.21 | −$13M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$9.7M | −$10.1M | — | -1.09 | −$7.2M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$10.8M | −$5.2M | — | -0.56 | −$7.8M | — | — | Aug 6 |
| Q4 2024 · Dec 31derived | $115K | −62.4% | — | −$10M | −$11.4M | — | -1.23 | −$9.5M | $55K | −$9.6M | Mar 9 |
| Q3 2024 · Sep 30 | $0 | −100.0% | — | −$11.3M | −$10.3M | — | -1.12 | −$6.3M | $100K | −$6.4M | Nov 14 |
| Q2 2024 · Jun 30 | $263K | — | — | −$10.2M | −$7.3M | — | -0.79 | −$7.7M | $53K | −$7.8M | Nov 14 |
| Q1 2024 · Mar 31 | $945K | — | — | −$11.4M | −$5M | — | -0.54 | −$10.8M | $129K | −$10.9M | Nov 14 |
| Q4 2023 · Dec 31derived | $305K | — | — | −$18.9M | −$22.9M | — | -3.85 | −$13.4M | $68K | −$13.5M | Mar 31 |
| Q3 2023 · Sep 30 | $1.3M | — | — | −$5.3M | −$5.1M | — | -0.97 | −$5.2M | $85K | −$5.3M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$49M | $13.3M | — | -0.79 | −$44.8M | $933K | −$45.7M | — | — |
| FY2024 · to Dec 31 | $1.3M | — | −$42.9M | −$34.1M | -2579.0% | -3.68 | −$34.3M | $337K | −$34.6M | — | — |
| FY2023 · to Dec 31 | $2.2M | — | −$38.1M | −$42.2M | -1884.5% | -7.64 | −$25.1M | $197K | −$25.3M | — | — |
| FY2022 · to Dec 31 | $23.9M | — | −$28.9M | −$18.7M | -78.4% | -4.31 | −$23.5M | $2.2M | −$25.6M | — | — |
| FY2021 · to Dec 31 | $60.9M | — | −$13.4M | −$17.1M | -28.2% | -0.63 | $2M | $10.9M | −$9M | — | — |
| FY2020 · to Dec 31 | $55.2M | — | $20.6M | $20.1M | 36.4% | 0.74 | $10M | $12.7M | −$2.7M | — | — |
Every number comes from SAB Biotherapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.